Does cilengitide deserve another chance?-Authors' reply

Lancet Oncol. 2014 Dec;15(13):e585-e586. doi: 10.1016/S1470-2045(14)71121-0. Epub 2014 Nov 24.

Authors

Roger Stupp¹, Martin Picard², Michael Weller³

Affiliations

¹ University Hospital Zurich, 8006 Zurich, Switzerland; European Organisation for Research and Treatment of Cancer, Brussels, Belgium. Electronic address: [email protected].
² Merck KGaA, Darmstadt, Germany.
³ University Hospital Zurich, 8006 Zurich, Switzerland; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.

PMID: 25456377
DOI: 10.1016/S1470-2045(14)71121-0

No abstract available

Publication types

Letter
Comment

MeSH terms

Brain Neoplasms / drug therapy*
DNA Modification Methylases / genetics*
DNA Repair Enzymes / genetics*
Dacarbazine / analogs & derivatives*
Female
Glioblastoma / drug therapy*
Humans
Male
Snake Venoms / therapeutic use*
Tumor Suppressor Proteins / genetics*

Substances

Snake Venoms
Tumor Suppressor Proteins
Dacarbazine
DNA Modification Methylases
DNA Repair Enzymes